WPD Pharmaceuticals Inc · CSE:WBIO
WPD Pharmaceuticals — Investor Presentation (May 2023)
21 slides from WPD Pharmaceuticals's investor presentation, May 2023
Slide 1: Investors presentation 5/2023
Investors presentation 5/2023
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward- looking statements. The words "believe"
Slide 3: About Us
About Us Innovative projects grants from National Cooperation with in important therapeutic Centre for Research Wake Forest University areas - oncology and Development School of Medicine (NCRD) (WFUSM) Global or regional Experienced team 4 active projects, market exclusivity of 20 experts from one i
Slide 4: Experienced Team
Experienced Team Mariusz Olejniczak Beata Pająk, D.Sc, PhD CEO & CO-FOUNDER CSO Experienced professional in clinical development - from planning and Habilitation and PhD in biotechnology with experience in the field of scientific advice through supervision to the closure and finalization of the medi
Slide 5: Glioblastoma market
Glioblastoma market US GBM treatment market Global GBM treatment market (million USD) (billion USD) 5 4,2 4 3 2,29 2 1 0 2021 2028 Almost 100% GBM will recur locally within 2 years after surgical and radiation therapy (60 Gy/30 fractions) with concomitant and adjuvant temozolomide Source: https://fi
Slide 6: Epidemiology – glioblastoma
Epidemiology – glioblastoma Glioblastoma is the most aggressive malignant primary brain tumor. Incidence rate - 3.19 per 100,000 persons in the United States 15 months - average patient survival rate after glioblastoma diagnosis if cancer is treated 3-4 months – average patient survival rate after d
Slide 7: Portfolio of drug candidates
Portfolio of drug candidates Preclinical Phase I Phase II Phase III MAA/EMA Rights Targeted indications Berubicin Regional Glioblastoma multiforme (GBM) recurrent WPD101a Global Glioblastoma multiforme (GBM) recurrent WPD103 Other tummors Global WPD101b Global Glioblastoma multiforme (GBM) recurrent
Slide 8: Berubicin (brain cancer)
Berubicin (brain cancer) Berubicin is a potential new drug that is one of the anthracyclines proven to cross the blood-brain barrier (BBB) and able to reach brain tumors. This discovery can potentially extend the clinical use of anthracyclines to brain tumors, specifically GBM. Berubicin 420 milion
Slide 9: Berubicin Clinical Development
Berubicin Clinical Development Screening After 2 Cycles After 6 Cycles After 7 Cycles (Day 2) (Day 44) (Day 170) (Day 191) Berubicin had one complete response to treatment during Phase I clinical trials. A “complete response” means no signs of cancer are visible on MRI. Berubicin’s Phase I clinical
Slide 10: Cooperation with WFUSM
Cooperation with WFUSM The solution's breakthrough is based on GBM-targeted therapy against IL-13RA2 and EphA2 – (brain tumor-specific receptors) conjugated with bacterial cytotoxins or other agents. It is well known that interleukin-13 receptor alpha 2 (IL-13RA2) is a glioblastoma receptor that is
Slide 11: Mechanism of action
Mechanism of action Figure 1. A schematic of the IL-13 receptor system. Normal and tumor cells express IL-4RA/IL-13RA1. IL-4 first binds to IL-4RA, then to the IL-13RA1 in normal cells. On the other hand, IL-13RA2 is expressed by tumor cells. IL-4 binds to IL- 4RA/IL-13RA1 but not IL-13RA2. IL-13 bi
Slide 12: Mechanism of action
Mechanism of action Figure 2. A schematic of the IL-13-based immunotoxins action. IL-13 conjugated to bacteria toxin specifically recognizes and binds to its IL- 13RA2 receptor. Receptor-ligand complex is internalized and transported within the cell. Further, bacteria toxin is released and inhibits
Slide 13: Development strategy
Development strategy Immunotoxins are fusion proteins comprised of a toxic moiety and a targeting moiety. That allows the concentration of the fusion protein at the plasma membrane of specific cell types. WPD101 is a unique drug cocktail composed of two immunotoxins targeting IL-13RA2 (WPD101a) and
Slide 14: IL-13RA2 expression in tumor tissues
IL-13RA2 expression in tumor tissues An elevated level of IL-13RA2 has been reported in various cancer types. However, only in glioma its overexpression is statistically significant. 14
Slide 15: EphA2 expression in tumor tissues
EphA2 expression in tumor tissues An elevated level of EphA2 has been reported in various cancer types. Confidential 15
Slide 16: U-251 LN-229 SNB-19
U-251 LN-229 SNB-19 T98G U-373 H4 EphA2 IL-13RA2 BTCOE 4536 BTCOE 4795 MDA-MB-231 T47D PC-3 fibroblasts EphA2 IL- 13RA2 4
Slide 17: The Phase I clinical trial in dogs with spontaneous malignant gliomas
The Phase I clinical trial in dogs with spontaneous malignant gliomas In the published study, 17 dogs diagnosed with glioma and immunohistochemically positive for IL-13RA2 (17/17) or/and EphA2 (11/17) receptors were treated with escalating doses of IL-13- and ephrinA1-based cytotoxins. Cytotoxins we
Slide 18: Gene expression pattern
Gene expression pattern Figure 3. Comparative transcriptional analysis of GBM signature gene expression patterns in human, canine, mouse and rat samples. 18
Slide 19: Scientific Advice in MHRA
Scientific Advice in MHRA In July 2020, WPD consulted MHRA in Scientific Advice procedure to discuss quality, non-clinical and regulatory aspects of WPD101a for the treatment of glioblastoma multiforme. MHRA accepted WPD drug development plan. 19
Slide 20: Current status
Current status WPD101 is currently in the preclinical stage of development. Its consistent anticancer properties are demonstrated and validated in dogs with spontaneous GBM resembling GBM in human patients. The canine model of spontaneous gliomas represents the closest translational model to human d
Slide 21: Contact
Contact mariusz.olejniczak@wpdpharmaceuticals.com www.wpdpharmaceuticals.com
WPD Pharmaceuticals — Investor Presentation (May 2023) on 6ix